• Josh Disbrow

    Josh Disbrow

    Chairman & Chief Executive Officer

    Josh Disbrow has been in the life sciences industry for over twenty years across pharmaceuticals, diagnostics, and medical devices. Prior to forming Aytu BioScience, Josh was the Chief Operating Officer of Ampio Pharmaceuticals (NYSE MKT: AMPE) and led the Luoxis Diagnostics subsidiary. Luoxis was merged into Aytu in April 2015 following Luoxis’ development of the technology behind the company’s MiOXSYS in vitro diagnostic platform. Prior to joining Ampio in 2012, he served as Vice President of Commercial Operations at Arbor Pharmaceuticals.

    Josh began as Arbor’s second employee and oversaw the commercialization of the company’s first product, scaling the commercial organization to over 150 people across sales, marketing, payer markets, distribution, commercial operations, and national accounts. In less than four years, Arbor grew from a company without any product revenues to a company with net sales of over $120 million. Prior to joining Arbor, he was the Director of Marketing at LipoScience (NASDAQ: LPDX), a cardiovascular in vitro diagnostic company. Josh also served in sales management at Cyberonics (Now LivaNova plc, NASDAQ: LIVN), a medical device company commercializing implantable neuromodulation devices. Josh started his career at Glaxo Wellcome (now GlaxoSmithKline plc), holding positions in both sales and marketing. He has a Master of Business Administration from Wake Forest University and Bachelor of Science in Management from North Carolina State University.

  • Jarrett Disbrow

    Jarrett Disbrow

    Chief Operating Officer

    Jarrett Disbrow is a seasoned pharmaceutical entrepreneur having been the founder of three pharmaceutical and life sciences companies over the past decade and broad industry experience spanning over twenty years.

    Most recently and prior to forming Aytu BioScience in April 2015, Jarrett was the President & CEO of Vyrix Pharmaceuticals, a specialty pharmaceutical company focused on male sexual dysfunction. Mr. Disbrow’s first pharmaceutical start-up was Arbor Pharmaceuticals, a company focused initially on pediatrics. As the sole founder of Arbor, Jarrett was responsible for the vision, fundraising, start-up, strategy and growth of the company until the acquisition by an investor group in 2010. Prior to founding Arbor Pharmaceuticals, he was head of marketing for Accentia Biopharmaceuticals, Inc. Jarrett began his career with GlaxoWellcome (now GlaxoSmithKline plc) where he held various roles in sales and marketing. He received a BS in Business Management from North Carolina State University in Raleigh, NC.

  • David Green

    David Green

    Chief Financial Officer

    David Green has been in the life sciences industry for over twenty-five years in scientific, operating and financial advisory roles. Prior to joining Aytu BioScience, David was the Chief Accounting Officer of Intarcia Therapeutics, a biopharmaceutical company engaged in late stage clinical development, where he was involved in IPO readiness and some of the largest private financing transactions in history for a pre-commercial, venture funded, life science company.

    David was Chief Financial Officer of Catheter Connections, a venture financed medical device company that was acquired by Merit Medical [NASDAQ: MMSI]; and CFO of Specialized Health Products International, a publicly traded medical device company that was acquired by C.R. Bard [NYSE: BCR].

    Prior to his operating roles, David advised a broad range of life science companies on issues of corporate finance and the use of strategic transactions to accelerate growth as a Managing Director of Duff & Phelps and as a member of Ernst & Young’s Palo Alto Center for Strategic Transactions®.  David began his career performing medical research after he received a Bachelor of Science in chemistry from the State University of New York.  He holds a Masters of Business Administration in finance from the University of Rochester and is a registered CPA.